Novel insights into mesothelioma biology and implications for therapy.

View/ Open
Date
2017-07Author
Yap, TA
Aerts, JG
Popat, S
Fennell, DA
Type
Journal Article
Metadata
Show full item recordAbstract
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.
Collections
Subject
Animals
Humans
Mesothelioma
Neovascularization, Pathologic
Ubiquitin Thiolesterase
Tumor Suppressor Proteins
Antineoplastic Agents
Antibodies, Monoclonal
Immunotherapy
Genes, Tumor Suppressor
Genes, Neurofibromatosis 2
Genes, p16
Proto-Oncogene Proteins c-akt
Protein-Arginine N-Methyltransferases
TOR Serine-Threonine Kinases
GPI-Linked Proteins
Tumor Microenvironment
Phosphoinositide-3 Kinase Inhibitors
Research team
Medicine Drug Development Unit (de Bono)
Thoracic Oncology
Language
eng
License start date
2017-07
Citation
Nature reviews. Cancer, 2017, 17 (8), pp. 475 - 488